Wall Street brokerages forecast that PRA Health Sciences Inc (NASDAQ:PRAH) will announce sales of $543.72 million for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for PRA Health Sciences’ earnings. The highest sales estimate is $546.98 million and the lowest is $540.60 million. PRA Health Sciences reported sales of $413.61 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 31.5%. The business is expected to issue its next quarterly earnings report on Wednesday, February 28th.

On average, analysts expect that PRA Health Sciences will report full year sales of $543.72 million for the current fiscal year, with estimates ranging from $1.92 billion to $1.93 billion. For the next year, analysts expect that the company will report sales of $2.33 billion per share, with estimates ranging from $2.29 billion to $2.36 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.03. The business had revenue of $494.55 million during the quarter, compared to analyst estimates of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business’s revenue was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.64 earnings per share.

A number of brokerages recently issued reports on PRAH. BidaskClub lowered shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. Zacks Investment Research upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $102.00 target price for the company in a research note on Thursday. Mitsubishi UFJ Financial Group assumed coverage on shares of PRA Health Sciences in a research note on Friday, December 15th. They set an “overweight” rating and a $102.00 target price for the company. Barclays assumed coverage on shares of PRA Health Sciences in a research note on Monday, December 11th. They set an “overweight” rating and a $94.00 target price for the company. Finally, Robert W. Baird set a $94.00 target price on shares of PRA Health Sciences and gave the company a “buy” rating in a research note on Friday, December 1st. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. PRA Health Sciences has an average rating of “Buy” and an average price target of $91.92.

Shares of PRA Health Sciences (NASDAQ PRAH) traded up $0.32 during trading hours on Wednesday, hitting $90.71. 476,125 shares of the company were exchanged, compared to its average volume of 504,812. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $5,770.00, a price-to-earnings ratio of 50.96, a PEG ratio of 1.26 and a beta of 0.41. PRA Health Sciences has a fifty-two week low of $54.08 and a fifty-two week high of $92.84.

In other news, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David W. Dockhorn sold 72,850 shares of the company’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $90.83, for a total transaction of $6,616,965.50. Following the transaction, the executive vice president now owns 72,850 shares of the company’s stock, valued at approximately $6,616,965.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 150,815 shares of company stock valued at $13,642,620. 2.10% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in PRAH. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of PRA Health Sciences by 12.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after acquiring an additional 160 shares during the last quarter. Carroll Financial Associates Inc. grew its position in shares of PRA Health Sciences by 127.4% during the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after acquiring an additional 790 shares during the last quarter. Comerica Bank bought a new position in shares of PRA Health Sciences during the third quarter worth about $214,000. Trustmark National Bank Trust Department bought a new position in shares of PRA Health Sciences during the second quarter worth about $225,000. Finally, Aperio Group LLC bought a new position in shares of PRA Health Sciences during the second quarter worth about $233,000. Institutional investors and hedge funds own 98.22% of the company’s stock.

WARNING: This report was originally posted by Marea Informative and is owned by of Marea Informative. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.mareainformativa.com/pra-health-sciences-inc-prah-expected-to-post-quarterly-sales-of-543-72-million-updated-updated-updated/124918/.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.